SEC Filing · DEF 14A
Biomea Fusion, Inc.
BMEANASDAQEQUITYCurrent
SEC Filing
Company context
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Current securities
As-filed source
As filedOpen full document ↗